Jnana launched in 2017, backed by an investor syndicate that includes Polaris Partners, Avalon Ventures, Versant Ventures, AbbVie Ventures, and Pfizer R&D Innovate.

Jnana Therapeutics Announces Positive Clinical Proof of Concept Achieved with JNT-517, a Potential First-in-Class Oral Treatment for PKU Jnana Therapeutics, Inc. Tue, Jan 30, 2024, 8:15 AM 5 min read ...

Jnana launched in 2017 with $50 million to build a platform that would enable the systematic discovery of drugs targeting SLCs. Although there are more than 400 proteins in this family, only 20 of ...

Jnana isn’t disclosing any specifics about its SLC targets yet, but it is focused on inflammatory and autoimmune diseases. And because the proteins are the gates for controlling the flux of ...

Jnana Therapeutics is launching into the clinic with more cash and enhanced collaborations. The company is tacking on an additional partnership with Roche as well as closing a $107 million series ...

Investors are betting that protein science will lead to new lines of attack on disease. Jnana Therapeutics Inc. is launching with $50 million and a plan to discover drugs for cancer and other ...

Jnana’s ongoing Phase 1 program of JNT-517 was initiated in Australia in the fourth quarter of 2022. The Phase 1a enrolled 64 healthy adults in a randomized, double-blind, placebo-controlled ...

BOSTON, July 19, 2023 (GLOBE NEWSWIRE) -- Jnana Therapeutics, a clinical-stage biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for challenging ...

Jnana should be developed through a deep study of Atma Jnana Sastras and association with the wise and the performance of virtuous actions without any expectation of fruits.